arrow_back Back to App

Supporting Lower Prescription Drug Prices for US Patients

This House Resolution affirms strong support for policies aimed at drastically lowering prescription drug costs in the US, aligning them with the lowest prices found in other developed nations. The goal is to ensure US citizens do not pay significantly more for the same medications, addressing the financial burden and lack of access currently faced by many Americans who skip doses or prescriptions due to high costs. The resolution supports expanding Medicare's ability to negotiate drug prices.
Key points
The House supports the principle that US patients should not be charged more for prescription drugs than patients in other developed countries.
Support is affirmed for expanding Medicare's drug price negotiation powers and promoting market competition to reduce treatment costs.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HRES_928
Sponsor: Rep. Dingell, Debbie [D-MI-6]
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Affirming support for most-favored-Nation drug pricing for United States patients.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HRES_928.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What are the main provisions?

Key points include:

  • The House supports the principle that US patients should not be charged more for prescription drugs than patients in other developed countries.
  • Support is affirmed for expanding Medicare's drug price negotiation powers and promoting market competition to reduce treatment costs.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Dingell, Debbie [D-MI-6].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health